Key result
Plozasiran, an APOC3 siRNA therapy, is being evaluated for its clinical potential in the management of severe hypertriglyceridemia.
Why the study?
Does plozasiran improve outcomes in patients with severe hypertriglyceridemia?
Does plozasiran improve outcomes in patients with severe hypertriglyceridemia?
This paper reviews the clinical potential of plozasiran, an APOC3 siRNA therapy, for treating severe hypertriglyceridemia.
Mild-to-moderate hypertriglyceridemia (HTG), defined as a fasting plasma triglyceride (TG) of 150-499 mg/dL (1.7-5.6 mmol/L), is a common clinical finding on biochemical laboratory testing. Epid...
No takes yet. Share an insight, caveat, or question.
Tang et al. (2024) studied this question. Plozasiran, an APOC3 siRNA therapy, is being evaluated for its clinical potential in the management of severe hypertriglyceridemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: